Alza receives European approval for Caelyx

AZA received marketing approval in Europe for its Caelyx pegylated liposomal doxorubicin to treat advanced ovarian cancer in women who have failed first-line platinum-based therapy. AZA marketing partner Schering-Plough (SGP), which markets Caelyx in Europe to treat AIDS-related Kaposi's sarcoma, also will market the product for the new indication. AZA markets the product in the U.S. under the name Doxil to treat metastatic ovarian cancer in women whose disease is refractory to paclitaxel- and platinum-based chemotherapy. ...